Garrett Tiana A, Davies-Cole John, Furness Bruce
From the *Epidemic Intelligence Service, Centers for Disease Control and Prevention (CDC), Atlanta, GA; †District of Columbia Department of Health, Washington, DC; and ‡Division of STD Prevention, NCHHSTP, CDC, Atlanta, GA.
Sex Transm Dis. 2015 Aug;42(8):413-6. doi: 10.1097/OLQ.0000000000000304.
In the District of Columbia (DC), Neisseria gonorrhoeae (gonorrhea) infections accounted for more than 25% of 9321 incident sexually transmitted infections reported in 2011; untreated infections can lead to reproductive complications and a higher risk for HIV transmission. In DC, limited capacity to measure the prevalence of antibiotic-resistant N. gonorrhoeae is available; culture-based antibiotic susceptibility testing (AST) is needed to monitor antimicrobial resistance. We examined the capacity of laboratories that report to the DC Department of Health to perform AST for ongoing surveillance of antibiotic-resistant N. gonorrhoeae and to identify suspected treatment failures.
We created a survey about diagnostic methods for gonorrhea testing and identified 33 laboratories that reported gonorrhea results to Department of Health in 2007 to 2012. Laboratories were assessed for use of bacterial culture or nucleic acid amplification testing (NAAT) for gonorrhea testing, prevalence of AST on gonorrhea-positive cultures, and types of antibiotics tested during AST. We estimated the prevalence of laboratory practices on the basis of self-report by staff.
Nineteen (58%) laboratories completed the survey, representing 92% of the gonorrhea reporting. Seventeen (89%) of 19 laboratories conducted testing by culture; only 6 (35%) performed AST; 79% performed NAAT. Barriers to AST included longer completion times and limited number of provider requests for AST. Commercial laboratories (32%) were more likely to conduct both culture and NAAT, compared with health care facilities (11%).
We report a low prevalence of laboratories performing AST because of multiple barriers. State-specific strategies addressing these barriers are needed to improve detection of antibiotic-resistant gonorrhea stains circulating among the population.
在哥伦比亚特区(DC),2011年报告的9321例新发性传播感染中,淋病奈瑟菌(淋病)感染占比超过25%;未经治疗的感染可导致生殖系统并发症,并增加艾滋病毒传播风险。在DC,测量耐抗生素淋病奈瑟菌流行率的能力有限;需要基于培养的抗生素敏感性试验(AST)来监测抗菌药物耐药性。我们检查了向DC卫生部报告的实验室进行AST以持续监测耐抗生素淋病奈瑟菌并识别疑似治疗失败病例的能力。
我们创建了一项关于淋病检测诊断方法的调查,并确定了2007年至2012年期间向卫生部报告淋病检测结果的33家实验室。评估实验室对淋病检测使用细菌培养或核酸扩增检测(NAAT)的情况、淋病阳性培养物上AST的流行率以及AST期间检测的抗生素类型。我们根据工作人员的自我报告估计实验室操作的流行率。
19家(58%)实验室完成了调查,占淋病报告的92%。19家实验室中有17家(89%)通过培养进行检测;只有6家(35%)进行AST;79%进行NAAT。AST的障碍包括完成时间较长以及AST的提供者请求数量有限。与医疗保健机构(11%)相比,商业实验室(32%)更有可能同时进行培养和NAAT。
我们报告称,由于多种障碍,进行AST的实验室比例较低。需要针对这些障碍制定各州特定的策略,以改善对人群中传播的耐抗生素淋病菌株的检测。